Author

R. G. Casner

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 3 Organism:virus· 2 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:proteomics· 1 Assay:structural biology· 1

Frequent Co-Authors

L. Shapiro· 4 shared D. D. Ho· 3 shared J. Yu· 3 shared L. Liu· 3 shared M. S. Nair· 3 shared P. D. Kwong· 3 shared Y. Huang· 3 shared G. Cerutti· 2 shared

Activity by Year

2021-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersMicrobiology

L. Shapiro

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Antibodies that neutralize all current SARS-CoV-2 variants of concern by conformational locking

L. Liu, R. G. Casner, Y. Guo, Q. Wang, S. Iketani, J. F.-W. Chan, J. Yu, B. Dadonaite, M. S. Nair, H. Mohri, E. R. Reddem, S. Yuan, V. K.-M. Poon, C. C.-S. Chan, K.-Y. Yuen, , D. D. Ho

This study identifies two antibodies that neutralize all SARS-CoV-2 variants by locking the spike protein in a down conformation, showing a novel mechanism and potential for prophylaxis.

bioRxiv · Apr 8, 2023 · PreprintMicrobiology

Potent and pan-neutralization of SARS-CoV-2 variants of concern by DARPins

V. K. Chonira, Y.-D. Kwon, J. Gorman, J. B. Case, Z. Ku, R. Simeon, R. G. Casner, D. R. Harris, A. S. Olia, T. Stevens, L. Shapiro, H. Boyd, Y. Tsybovsky, F. Krammer, M. Diamond, , Z. Chen

This paper reports the development of two DARPins, FSR16m and FSR22, that potently neutralize SARS-CoV-2 variants, including emerging ones, with efficacy comparable to therapeutic antibodies.

bioRxiv · May 30, 2022 · PreprintBioengineering

A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses

P. Wang, R. G. Casner, M. S. Nair, J. Yu, Y. Guo, M. Wang, J. F. W. Chan, G. Cerutti, S. Iketani, L. Liu, Z. Sheng, Z. Chen, K.-Y. Yuen, P. D. Kwong, Y. Huang, , D. D. Ho

This paper identifies a monoclonal antibody, 2-36, that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses, with a conserved epitope in the RBD identified through cryo-EM.

bioRxiv · Oct 13, 2021Microbiology

Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization

P. Wang, R. G. Casner, M. S. Nair, M. Wang, J. Yu, G. Cerutti, L. Liu, P. D. Kwong, Y. Huang, L. Shapiro, D. D. Ho

This study shows the SARS-CoV-2 P.1 variant is more resistant to antibody neutralization than previous variants, but less affected by vaccine-induced immunity.

bioRxiv · Mar 1, 2021Microbiology